See more : Zhejiang Starry Pharmaceutical Co.,Ltd. (603520.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Carisma Therapeutics, Inc. (CARM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Carisma Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Ishaan Infrastructures and Shelters Limited (IISL.BO) Income Statement Analysis – Financial Results
- Tomoegawa Co., Ltd. (3878.T) Income Statement Analysis – Financial Results
- Advice Capital Globale (ACIGLO.CO) Income Statement Analysis – Financial Results
- Accell Group N.V. (AO1B.DE) Income Statement Analysis – Financial Results
- Annabidiol Corp. (ACBD) Income Statement Analysis – Financial Results
Carisma Therapeutics, Inc. (CARM)
About Carisma Therapeutics, Inc.
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.92M | 9.83M | 26.54M | 11.24M | 0.00 | 0.00 | 425.00K | 29.98M | 990.00K | 2.24M | 1.33M | 0.00 | 0.00 |
| Cost of Revenue | 74.13M | 6.09M | 85.00K | 0.00 | 219.00K | 208.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -59.21M | 3.74M | 26.46M | 11.24M | -219.00K | -208.00K | 425.00K | 29.98M | 990.00K | 2.24M | 1.33M | 0.00 | 0.00 |
| Gross Profit Ratio | -396.85% | 38.07% | 99.68% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 74.13M | 56.62M | 34.39M | 23.29M | 24.44M | 13.87M | 12.23M | 12.20M | 25.97M | 26.70M | 13.79M | 15.26M | 9.41M |
| General & Administrative | 29.53M | 9.38M | 6.41M | 5.09M | 12.21M | 11.62M | 8.07M | 14.74M | 9.85M | 8.47M | 4.02M | 4.21M | 3.27M |
| Selling & Marketing | 0.00 | 30.41M | 0.00 | 0.00 | 0.00 | 0.00 | -170.00K | -3.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 29.53M | 3.29M | 6.41M | 5.09M | 12.21M | 11.62M | 7.90M | 11.44M | 9.85M | 8.47M | 4.02M | 4.21M | 3.27M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 103.65M | 59.91M | 40.79M | 28.38M | 36.65M | 25.49M | 20.13M | 23.64M | 35.82M | 35.17M | 17.81M | 19.48M | 12.68M |
| Cost & Expenses | 103.65M | 66.00M | 40.79M | 28.38M | 36.87M | 25.70M | 20.41M | 23.82M | 36.19M | 35.17M | 17.81M | 19.48M | 12.68M |
| Interest Income | 1.94M | 1.85M | 10.00K | 29.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 3.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 247.00K | 1.40M | 376.00K | 1.40M | 168.00K | 151.00K |
| Depreciation & Amortization | 2.84M | 6.09M | 85.00K | 122.00K | 219.00K | 208.00K | 285.00K | 178.00K | 366.00K | 410.00K | 438.00K | 448.00K | 364.00K |
| EBITDA | -85.89M | -51.99M | -40.11M | -27.93M | -107.28M | -33.49M | -28.74M | 2.32M | -31.69M | -33.37M | -17.18M | -19.04M | -12.31M |
| EBITDA Ratio | -575.74% | -509.17% | -151.12% | -248.58% | 0.00% | 0.00% | -4,635.29% | 21.16% | -3,518.18% | -1,487.74% | -1,213.42% | 0.00% | 0.00% |
| Operating Income | -88.73M | -56.16M | -40.79M | -28.38M | -36.87M | -25.70M | -19.99M | 6.17M | -35.20M | -33.78M | -16.63M | -19.49M | -12.68M |
| Operating Income Ratio | -594.75% | -571.10% | -153.68% | -252.56% | 0.00% | 0.00% | -4,702.35% | 20.57% | -3,555.15% | -1,506.02% | -1,246.25% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.85M | -5.06M | 10.00K | 29.00K | -70.63M | -7.99M | -9.04M | -4.27M | 1.74M | -1.23M | -1.40M | -168.00K | -151.00K |
| Income Before Tax | -86.88M | -61.23M | -40.78M | -28.35M | -107.50M | -33.69M | -29.03M | 1.90M | -33.45M | -34.16M | -18.03M | -19.66M | -12.83M |
| Income Before Tax Ratio | -582.34% | -622.60% | -153.65% | -252.31% | 0.00% | 0.00% | -6,830.35% | 6.32% | -3,378.99% | -1,522.78% | -1,351.20% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.88M | -10.00K | -29.00K | 0.00 | 46.86K | 0.00 | 5.00K | 1.40M | 376.00K | 1.40M | 168.00K | 151.00K |
| Net Income | -86.88M | -61.23M | -40.77M | -28.32M | -107.50M | -33.69M | -29.03M | 1.89M | -33.45M | -34.53M | -19.43M | -19.83M | -12.98M |
| Net Income Ratio | -582.34% | -622.60% | -153.61% | -252.05% | 0.00% | 0.00% | -6,830.35% | 6.31% | -3,378.99% | -1,539.55% | -1,456.15% | 0.00% | 0.00% |
| EPS | -2.59 | -575.42 | -4.47 | -4.79 | -23.64 | -10.91 | -22.24 | 1.79 | -35.23 | -47.16 | -45.50 | -55.70 | -30.39 |
| EPS Diluted | -2.59 | -575.42 | -4.47 | -4.79 | -23.64 | -10.91 | -22.24 | 1.74 | -35.23 | -47.16 | -45.50 | -55.70 | -30.39 |
| Weighted Avg Shares Out | 33.52M | 106.40K | 9.12M | 5.91M | 4.55M | 3.09M | 1.31M | 1.05M | 949.65K | 732.20K | 426.95K | 355.90K | 426.95K |
| Weighted Avg Shares Out (Dil) | 33.52M | 106.40K | 9.12M | 5.91M | 4.55M | 3.09M | 1.31M | 1.09M | 949.65K | 732.20K | 426.95K | 355.90K | 426.95K |
SESN News: Why Biotech Penny Stock Sesen Bio Is Skryocketing Today
Sesen Bio (SESN) stock is rising higher on Wednesday after revealing plans to meet with the U.S. Food and Drug Administration. The post SESN News: Why Biotech Penny Stock Sesen Bio Is Skryocketing Today appeared first on InvestorPlace.
Sesen Bio Shares Gain On FDA Type A Meeting On Issues From Vicineum Response Letter
The FDA has granted Sesen Bio Inc's (NASDAQ: SESN) request for a Type A meeting to discuss the Chemistry, Manufacturing, and Controls (CMC) issues raised in the Complete Response Letter for Vicineum for BCG-unresponsive non-muscle invasive bladder cancer. Related: Sesen Bio Stock...
SESN Stock: Why The Price Increased By Over 15% Pre-Market
The stock price of Sesen Bio Inc (NASDAQ: SESN) increased by over 15% pre-market. This is why it happened.
Why Sesen Bio Stock Is Trading Higher Higher During Tuesday's After-Hours Session
Shares of Sesen Bio Inc. (NASDAQ: SESN) were trading sharply higher following a company announcement that the FDA granted its request for a Type A Meeting to discuss the issues brought up within the complete response letter (CRL) response to...
Best Penny Stocks to Buy Now? Check These 3 Out in October
Which penny stocks are you watching right now? The post Best Penny Stocks to Buy Now?
SESN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Sesen Bio, Inc. Investors With Losses Exceeding $400K of Class Action and Lead Plaintiff Deadline: October 18, 2021
New York, New York--(Newsfile Corp. - October 18, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Sesen Bio, Inc. ("Sesen Bio" or the "Company") (NASDAQ: SESN) and certain of its...
SESN Final Deadline Today: Rosen, Global Investor Counsel, Encourages Sesen Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 18 Deadline in Securities Class Action - SESN
New York, New York--(Newsfile Corp. - October 18, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Sesen Bio, Inc. (NASDAQ: SESN) between December 21, 2020 and August 17, 2021, inclusive...
3 Penny Stocks Waiting on FDA Approval for Rocket Fuel
Several penny stocks out there have done very well recently but these three biotechs are waiting for positive FDA news to soar higher. The post 3 Penny Stocks Waiting on FDA Approval for Rocket Fuel appeared first on InvestorPlace.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Sesen Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 18, 2021 - SESN
New York, New York--(Newsfile Corp. - October 18, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Sesen Bio, Inc. (NASDAQ: SESN) ("Sesen Bio") between December 21,...
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SESN, HYRE and APPH
NEW YORK, NY / ACCESSWIRE / October 17, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the...
Source: https://incomestatements.info
Category: Stock Reports